Compare Amylx Pharmaceuticals Inc (AMLX) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs KKR & Co Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while KKR & Co Inc trades at $96.68 (market cap $87.04B). The key difference: KKR & Co Inc is far larger — about 44× Amylx Pharmaceuticals Inc's market cap, and KKR & Co Inc pays a 0.77% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KKR | |
|---|---|---|
Market Cap | $1.98B | $87.04B |
Sector | Health | Financials |
52-Week High | $18.70 | $152.16 |
52-Week Low | $7.64 | $83.88 |
Enterprise Value | $1.70B | $12.56B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
KKR trades at $96.94, up 0.7% today, with a bullish technical outlook supported by moving averages and near-term resistance at $97. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic acquisitions like the $4.2 billion EDF power solutions deal and a $1.3 billion renewable energy platform in South Korea. Strong analyst sentiment includes 24 buy ratings and a consensus price target of $127.71, indicating significant upside potential.
The outlook for KKR is positive, driven by robust monetization activity, strategic growth initiatives, and a favorable analyst consensus. Key risks include volatile cash flows from operations, high leverage with long-term debt of $49.91 billion, and dependence on private market conditions. Investors should weigh the growth opportunities against these financial and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
